Cetrotide (F)

Each vial contains 0.25 mg cetrorelix (as acetate).

After reconstitution with the solvent provided, each mL of the solution contains 0.25 mg cetrorelix. Cetrotide 0.25mg powder and solvent for solution for injection is indicated for the prevention of premature ovulation in patients undergoing a controlled ovarian stimulation, followed by oocyte pick-up and assisted reproductive techniques.

In clinical trials Cetrotide was used with human menopausal gonadotropin (HMG), however, limited experience with recombinant follicle-stimulating hormone (FSH) suggested similar efficacy.

The first administration of Cetrotide should be performed under the supervision of a physician and under conditions where treatment of possible allergic/pseudo-allergic reactions (including life-threatening anaphylaxis) is immediately available. The following injections may be self-administered as long as the patient is made aware of the signs and symptoms that may indicate hypersensitivity, the consequences of such a reaction and the need for immediate medical intervention.

Available on request.

Available on request.